Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Receives Consensus Rating of “Reduce” from Brokerages

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) have earned a consensus rating of “Reduce” from the eleven analysts that are currently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a sell recommendation and six have given a hold recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $22.45.

Several research analysts recently weighed in on the company. Sanford C. Bernstein started coverage on Fresenius Medical Care AG & Co. KGaA in a research note on Thursday, July 16th. They set a “market perform” rating on the stock. Truist Financial set a $25.00 price target on Fresenius Medical Care AG & Co. KGaA in a research note on Wednesday. Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Wednesday, May 6th. Weiss Ratings downgraded Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Finally, Citigroup restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday, July 17th.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

A number of institutional investors have recently bought and sold shares of the stock. Pzena Investment Management LLC grew its position in Fresenius Medical Care AG & Co. KGaA by 2.0% during the 1st quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company’s stock worth $339,592,000 after purchasing an additional 299,986 shares during the last quarter. Morgan Stanley increased its stake in Fresenius Medical Care AG & Co. KGaA by 47.2% during the 4th quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock valued at $70,027,000 after purchasing an additional 942,497 shares in the last quarter. Integral Health Asset Management LLC raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 44.4% in the fourth quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $15,483,000 after buying an additional 200,000 shares during the last quarter. Moran Wealth Management LLC raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 31.5% in the first quarter. Moran Wealth Management LLC now owns 347,773 shares of the company’s stock worth $7,846,000 after buying an additional 83,311 shares during the last quarter. Finally, Quantinno Capital Management LP lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 15.7% during the first quarter. Quantinno Capital Management LP now owns 341,343 shares of the company’s stock worth $7,701,000 after buying an additional 46,428 shares during the period. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Price Performance

Shares of FMS opened at $23.91 on Thursday. The company has a market cap of $12.84 billion, a price-to-earnings ratio of 12.39, a price-to-earnings-growth ratio of 4.27 and a beta of 0.77. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $20.02 and a twelve month high of $27.64. The company has a quick ratio of 0.86, a current ratio of 1.07 and a debt-to-equity ratio of 0.78. The company has a 50 day moving average of $23.49 and a two-hundred day moving average of $22.99.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings results on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%.The business had revenue of $5.55 billion for the quarter, compared to the consensus estimate of $5.48 billion. As a group, analysts predict that Fresenius Medical Care AG & Co. KGaA will post 2.22 earnings per share for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.